Skip to main content

Ragwitek FDA Approval History

FDA Approved: Yes (First approved April 17, 2014)
Brand name: Ragwitek
Generic name: ragweed pollen allergen extract
Company: Merck
Treatment for: Allergic Rhinitis

Ragwitek (short ragweed pollen allergen extract) is a sublingual immunotherapy for the treatment of ragweed allergies.

Development timeline for Ragwitek

DateArticle
Apr 19, 2021Approval U.S. FDA Approves ALK's Ragwitek (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Children and Adolescents With Short Ragweed Pollen-Induced Allergic Rhinitis With or Without Conjunctivitis
Apr 17, 2014Approval FDA Approves Ragwitek for Short Ragweed Pollen Allergies
Jan 28, 2014Merck Statement on FDA Advisory Committee Meeting for Ragwitek™ (Short Ragweed Pollen Allergen Extract), an Investigational Sublingual Allergy Immunotherapy Tablet

See also

Ragwitek (ragweed pollen allergen extract) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer